Runt-related transcription factor 2/acute myeloid leukemia 3 protein (RUNX2, AML-3) is a Runt DNA-binding domain transcription factor that facilitates osteoblast differentiation and skeletal morphogenesis.
Synonyms: RUNX2 Antibody - Anti-RUNX2 antibody produced in rabbit; Runx2 Antibody; Anti-Acute myeloid leukemia 3 protein; Anti-CBF-alpha-1; Anti-Core-binding factor subunit alpha-1; Anti-OSF-2; Anti-Oncogene AML-3; Anti-PEA2-alpha A; Anti-PEBP2-alpha A; Anti-Polyomavirus enhancer-binding protein 2 alpha A subunit; Anti-Runt-related transcription factor 2; Anti-SL3-3 enhancer factor 1 alpha A subunit; Anti-SL3/AKV core-binding factor alpha A subunit
MDL Number: MFCD07370486
Storage: -20C
Application: Rabbit polyclonal anti-RUNX2 antibody is used to tag Runt-related transcription factor 2/Acute myeloid leukemia 3 protein for detection and quantitation by immunocytochemical and immunohistochemical (IHC) techniques. It is used as a probe to determine the presence and roles of runt-related transcription factor 2/Acute myeloid leukemia 3 protein in osteoblast differentiation and skeletal morphogenesis.
Biochem Physiol Actions: Runt-related transcription factor 2/ acute myeloid leukemia 3 protein (RUNX2, AML-3) mediates osteoblast differentiation and skeletal morphogenesis. It promotes mesenchymal cell differentiation in osteoblasts and its maturation. Elevated levels of RUNX2 is observed in bone?metastatic cancers. The post-translational modifications like phosphorylation, methylation, glycosylation and ubiquitination in the RUNX2 modulates osteogenesis. Mutations in the RUNX2 gene leading to loss of function is implicated in cleidocranial dysplasia (CCD). The levels of RUNX2 is elevated in osteosarcoma.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC